Drugs / Nemvaleukin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05092360 | Jan 2022 → Jan 2025 | fallopian tube carcinoma, primary peritoneal carcinoma, refractory malignant neoplasm | Mural Oncology, Inc | Terminated | No outcome recorded Stop: Business |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-10-26 | Alkermes, Inc. | Alkermes Initiates ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer alkermes.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nemvaleukin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05092360 ↗ |
| Action | Activate | “Nemvaleukin preferentially activates cytotoxic CD8+ T cells and natural killer cells with minimal, non-dose-dependent effects on CD4+ regulatory T cells.” PMID 37334673 ↗ Jun 2023 |
| Modality | Protein / enzyme biologic | “Nemvaleukin alfa (nemvaleukin, ALKS 4230) is a novel cytokine designed to capture and expand the therapeutic potential of high-dose interleukin-2 (IL-2) while mitigating its...” PMID 37334673 ↗ Jun 2023 |
| Route | Intravenous | “IV infusion over 30 minutes” NCT05092360 ↗ |